Johnson & Johnson has reached an agreement with the Trump Administration to lower drug prices, making medications more affordable for Americans. The company’s pharmaceutical products will be exempt from tariffs, with specific terms remaining confidential. Johnson & Johnson will also build two new manufacturing facilities in North Carolina and Pennsylvania as part of a $55 billion U.S. investment plan to support domestic manufacturing and technology advancements. The company will participate in the TrumpRx.gov platform, allowing patients to purchase medicines at reduced prices. This collaboration aims to provide accessible healthcare while boosting the U.S. economy and innovation in the healthcare sector.

Read more at Nasdaq: Johnson & Johnson In Deal With Trump Administration To Cut Drug Prices, Get Tariff Exemption